Concepedia

Author

Amy Newlands

GlaxoSmithKline (United Kingdom)

Also Known As

A Newlands, Amy H Newlands, Amy H. Newlands, Amy Newlands, Newlands A

22

Publications

409

Citations

9

H-Index

13

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)Research Triangle Park FoundationGlaxoSmithKline (United States)
AN

About

Amy Newlands is an author at GlaxoSmithKline (United Kingdom) specializing in medicine, asthma, and allergy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

190

2

Allergy

1

1

178

3

Immunology

1

1

178

4

Pharmacology

1

1

12

5

Pulmonary Disease

1

1

12

Amy Newlands

×

8

Publications

377

Citations

8

H-Index

YearCitations

Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: A double-blind randomized controlled trial

Saifudin Khalid, Robert Murdoch, Amy Newlands,

Journal of Allergy and Clinical Immunology

2014

178

Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial

Jinping Zheng, Teresita De Guia, Jie Wang‐Jairaj,

Current Medical Research and Opinion

2015

51

Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial

Chris Kalberg, Dianne M. O’Dell, Dmitry Galkin,

Drugs in R&D

2016

41

Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study

J Zheng, Nanshan Zhong, Amy Newlands,

International Journal of COPD

2015

35

Inhibition of capsaicin‐driven nasal hyper‐reactivity by <scp>SB</scp>‐705498, a <scp>TRPV</scp>1 antagonist

Carlijn Holland, Cornelis M. van Drunen, Jane Denyer,

British Journal of Clinical Pharmacology

2013

31

Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial

Chika Akinseye, Courtney Crim, Amy Newlands,

PLoS ONE

2023

15

TRPV1 inhibition does not prevent cold dry air-elicited symptoms in non-allergic rhinitis

Robert Murdoch, Philippe Bareille, Jane Denyer,

International Journal of Clinical Pharmacology and Therapeutics

2014

14

Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults

Rashmi Mehta, Kelly Hardes, Anthony Cahn,

2011

12

Page 1